# Treatment of Basal Cell Carcinoma (BCC) of the Skin, of the Morpheiform, Infiltrative, and Noduloulcerative Types in Inoperable Patients and Not Suitable for Radiotherapy Using Formulated Methylene Blue

> **NCT07311070** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Daryoush Hamidi Alamdari, PhD** · enrollment: 20 (estimated)

## Conditions studied

- Advanced Basal Cell Carcinoma (BCC)
- Inoperable Disease
- Morpheaform Basal Cell Carcinoma
- Noduloulcerative Basal Cell Carcinoma
- Infiltrative Basal Cell Carcinoma

## Interventions

- **DRUG:** Formulated Topical Methylene Blue (0.5 mg/mL)
- **DRUG:** Wound Healing Gel

## Key facts

- **NCT ID:** NCT07311070
- **Lead sponsor:** Daryoush Hamidi Alamdari, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-10-21
- **Primary completion:** 2026-01-20
- **Final completion:** 2026-01-20
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07311070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07311070, "Treatment of Basal Cell Carcinoma (BCC) of the Skin, of the Morpheiform, Infiltrative, and Noduloulcerative Types in Inoperable Patients and Not Suitable for Radiotherapy Using Formulated Methylene Blue". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07311070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*